Cresar H Tablet is a medicine that is used for the treatment of blood pressure, Fluid Retention, Heart Failure, Liver Failure, Kidney Failure, Kidney Disorder and other conditions.
Cresar H Tablet contains Hydrochlorothiazide, and Telmisartan as active ingredients.
Cresar H Tablet works by eliminating the fluid and salts from the body; blocking the action of a substance responsible for narrowing the blood vessels;
Cresar H Tablet Uses
- Blood Pressure
- Fluid Retention
- Heart Failure
- Liver Failure
- Kidney Failure
- Kidney Disorder
- High Blood Pressure
- Heart Attack
- Kidney Failure In Patients With Diabetes
Cresar H Tablet Working, Mechanism of Action and Pharmacology
- Eliminating the fluid and salts from the body.
- Blocking the action of a substance responsible for narrowing the blood vessels.
Cresar H Tablet – Composition and Active Ingredients
- Hydrochlorothiazide (12.5 MG)
- Telmisartan (40 MG)
Cresar H Tablet – Side-effects
- Dry Mouth
- Electrolyte Imbalance
- Gastrointestinal Problems
- Excess Of Uric Acid In The Blood
Cresar H Tablet – Precautions & How to Use
Avoid taking hydrochlorothiazide at bedtime because it makes you urinate more often
Consult your doctor if you experience dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, confusion, muscle pains or cramps
Do not chew, divide or crush the tablets
Drink adequate amount of liquid to avoid becoming dehydrated or overheated
Get your blood pressure, potassium and kidney function checked 1 week after starting this medicine
Swallow whole tablet with water
Cresar H Tablet – Drug Interactions
- Acetylsalicylic acid
Cresar H Tablet – Contraindications
- Allergic reactions
- Heart disease
Cresar H Tablet – Packages and Strengths
- Cresar H Tablet – Packages: 10 Tablet
- Cresar H Tablet – Strengths: 80MG+12.5MG, 40MG+12.5MG, 40+12.5
Mechanism of Action of Cresar H 40mg Tab 10s:
Telmisartan Is A Nonpeptide AT1 Angiotensin II Receptor Antagonist. Exerts Antihypertensive Activity By Preventing Angiotensin II From Binding To AT1 Receptors Thus Inhibiting The Vasoconstriction And Aldosterone-Secreting Effects Of Angiotensin II. Absorption: Rapidly Absorbed. Dose Dependent Bioavailability 42% (After 40 Mg Dose); 58% (After 160-Mg Dose). Peak Plasma Concentrations: 0.5-1hr. Distribution: Protien Binding: 99%. Metabolism: Undergoes Conjugation With Glucuronic Acid To Form Inactive Metabolites. Excretion: Excreted Almost Entirely As Unchanged Drug In Faeces Via Bile. <1% Excreted Via Urine. Terminal Elimination Half-Life: 24 Hr.
Special Precautions for Cresar H 40mg Tab 10s:
Hepatic Insufficiency, Biliary Obstruction, Renal Impairment, Renaly Artery Stenosis. Correct Volume Depletion Before Initiating Treatment. Monitor Serum Potassium Levels Regularly, Especially In Elderly And Renally-Impaired Patients.
Dosage and Administration
The usual initial dosage is one tablet of CRESAR-H daily.
A patient whose blood pressure is not adequately controlled with telmisartan monotherapy 40 mg may be switched to CRESAR-H. The dose may be increased, if necessary, to two tablets of CRESAR-H or one tablet of CRESAR 80 H daily.
A patient whose blood pressure is not adequately controlled with telmisartan monotherapy 80 mg may be switched to one tablet of CRESAR80 H daily. If blood pressure remains uncontrolled after 2-4 weeks of therapy the dose may be increased to two tablets of CRESAR80 H once daily.
A patient whose blood pressure is not adequately controlled with hydrochlorothiazide 25 mg once daily may be switched to CRESAR-H or CRESAR80 H once daily. If blood pressure remains uncontrolled after 2-4 weeks of therapy the dose may be increased to two tablets of CRESAR80 H once daily.
Patients controlled by 25 mg hydrochlorothiazide but who experience hypokalemia with this regimen may be switched to CRESAR80 H once daily, reducing the dose of hydrochlorothiazide without reducing the overall expected antihypertensive response.
CRESAR-H/CRESAR80 H may be administered with other antihypertensive agents. It may be administered with or without food.
The combination may be substituted for the titrated components.
Patients with depletion of intravascular volume should have the condition corrected or telmisartan tablets should be initiated under close medical supervision. Patients with biliary obstructive disorders or hepatic insufficiency should have treatment started under close medical supervision
Patients with Renal Impairment
The usual regimens of therapy with CRESAR-H/CRESAR80 H may be followed as long as the patient’s creatinine clearance is more than 30 mL/min. In patients with more severe renal impairment, CRESAR-H/CRESAR80 H is not recommended.
Patients with Hepatic Impairment
CRESAR-H/CRESAR80 H is not recommended for patients with severe hepatities impairment. Patients with biliary obstructive disorders or hepatic impairment should have treatment started with CRESAR-H under close medical supervision.
For more information visit us our website: www.medypharma.com